Akari Therapeutics Plc

Stage 2 · Advancing · week 1

As of Oct 22, 2026, Akari Therapeutics is in Stage 2, the uptrend phase, now in its first week (since Oct 21, 2026). It closed at $8.10, 75.3% below its 52-week high and below its 200-day average, which is falling.

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. More about the company

$8.10

-7.53% today

$18.5M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is AKTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 35w

S4 18w

S4 49w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 8w → S4 35w → S1 5w → S2 10w → S3 8w → S4 18w → S1 2w → S4 3w → S1 8w → S4 49w → S1 8w → S2 1w → S1 1w → S4 10w → S2 1w current

Total tracked: 165 weeks across 15 stage runs.

AKTX among Biotechnology437th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…437	AKTXAkari Therapeutics Plc	Stage 2 · wk 1	14	−16.1%

vs 52W High

-75.3%

$3.06 lo$32.80 hi

75.3% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 1

1w13w26w

Week 1, fresh breakout

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-11.4%

200 DMA: $9.15 · sloping down

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.30x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-16.1%

-6.9%

+35.0%

YTD

-30.2%

-73.1%

Scan Membership

Breakout Watch

Latest: 2024-07-22

4 appearances in last 60 days. First seen: 2019-03-13.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 1 · Vol 0.30x

2026-10-21S24→2

Wk 1 · Vol 0.41x

2026-10-20S4

Wk 10 · Vol 0.50x

2026-10-19S4

Wk 10 · Vol 1.13x

2026-10-16S4

Wk 10 · Vol 0.31x

2026-10-15S4

Wk 9 · Vol 0.81x

2026-10-14S4

Wk 9 · Vol 0.51x

2026-10-13S4

Wk 9 · Vol 0.27x

2026-10-12S4

Wk 9 · Vol 1.69x

2026-10-09S4

Wk 9 · Vol 1.15x

2026-10-08S4

Wk 8 · Vol 0.95x

2026-10-07S4

Wk 8 · Vol 0.50x

Moving averages & range

50 DMA

$9.20

200 DMA

$9.15

52W High

$32.80

52W Low

$3.06

5D Low

$8.10

Resistance levels (recent highs)

20d High

$9.89

60d High

$11.47

120d High

$22.05

250d High

$32.80

Next resistance

+22.1%

to 20d High

ROE

-140.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.8

Akari Therapeutics: quick answers

What stage is Akari Therapeutics in?

As of Oct 22, 2026, Akari Therapeutics (AKTX) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is Akari Therapeutics in an uptrend?

Yes. Akari Therapeutics is in a Stage 2 uptrend. It trades 11.4% below its 200-day average, which is falling.

How far is Akari Therapeutics from its 52-week high?

Akari Therapeutics closed at $8.10 on Oct 22, 2026, 75.3% below its 52-week high of $32.80. Its 52-week low is $3.06.

How has Akari Therapeutics performed over the past year?

As of Oct 22, 2026, Akari Therapeutics is down 73.1% over the past year and down 30.2% so far in 2026.

Which sector and industry is Akari Therapeutics in?

Akari Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.